Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.25 -1.2%	$0.27	$0.20 ▼ $1.48	$67.06M	2.24	1.69 million shs	647,319 shs
ADMA ADMA Biologics	$17.74 -2.2%	$20.91	$10.21 ▼ $25.67	$4.24B	0.47	3.70 million shs	6.74 million shs
IBRX ImmunityBio	$2.87 +1.1%	$2.67	$1.83 ▼ $7.63	$2.53B	0.14	6.06 million shs	9.12 million shs
INBX Inhibrx Biosciences	$14.93 -1.8%	$12.79	$10.80 ▼ $17.79	$216.13M	N/A	100,859 shs	132,762 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-1.17%	+4.42%	-8.00%	-13.00%	-71.25%
ADMA ADMA Biologics	-2.15%	-14.75%	-11.83%	-10.40%	+67.04%
IBRX ImmunityBio	+1.06%	-6.51%	+8.30%	+5.90%	-53.93%
INBX Inhibrx Biosciences	-1.84%	+2.47%	+13.45%	+4.04%	+2.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.5794 of 5 stars	4.2	5.0	0.0	0.0	0.8	0.0
ADMA ADMA Biologics	3.6203 of 5 stars	3.7	1.0	0.0	2.0	2.5	3.1
IBRX ImmunityBio	1.9059 of 5 stars	3.6	2.0	0.0	0.6	1.7	0.6
INBX Inhibrx Biosciences	2.4365 of 5 stars	0.0	3.0	4.6	0.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	500.13% Upside
ADMA ADMA Biologics	3.33	Buy	$27.67	55.96% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	326.83% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADMA, ADAP, INBX, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/5/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.38	N/A	N/A	$0.05 per share	5.06
ADMA ADMA Biologics	$426.45M	9.93	$0.54 per share	32.78	$1.48 per share	11.99
IBRX ImmunityBio	$14.74M	171.85	N/A	N/A	($0.57) per share	-5.04
INBX Inhibrx Biosciences	$200K	1,080.93	$114.85 per share	0.13	$9.23 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
ADMA ADMA Biologics	$197.67M	$0.85	20.87	25.71	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.13	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)

Latest ADMA, ADAP, INBX, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
ADMA ADMA Biologics	0.22	6.58	3.36
IBRX ImmunityBio	N/A	2.22	2.05
INBX Inhibrx Biosciences	1.04	5.12	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ADMA ADMA Biologics	75.68%
IBRX ImmunityBio	8.58%
INBX Inhibrx Biosciences	82.46%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ADMA ADMA Biologics	3.50%
IBRX ImmunityBio	76.79%
INBX Inhibrx Biosciences	17.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable

ADMA, ADAP, INBX, and IBRX Headlines

Recent News About These Companies

Nuveen Asset Management LLC Makes New $385,000 Investment in Inhibrx, Inc. (NASDAQ:INBX)

June 6, 2025 | marketbeat.com

Inhibrx, Inc. (NASDAQ:INBX) Shares Sold by Alpha Wealth Funds LLC

June 4, 2025 | marketbeat.com

Deutsche Bank AG Takes $302,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

June 1, 2025 | marketbeat.com

Millennium Management LLC Buys Shares of 258,388 Inhibrx, Inc. (NASDAQ:INBX)

May 31, 2025 | marketbeat.com

Alpha Wealth Funds LLC Buys New Stake in Inhibrx, Inc. (NASDAQ:INBX)

May 29, 2025 | marketbeat.com

116,104 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by Northern Trust Corp

May 28, 2025 | marketbeat.com

Jane Street Group LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)

May 22, 2025 | marketbeat.com

Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President

April 3, 2025 | investing.com

Inhibrx announces leadership changes as co-founder departs

April 2, 2025 | thepharmaletter.com

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

April 1, 2025 | prnewswire.com

Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations

March 19, 2025 | finance.yahoo.com

Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

March 18, 2025 | finanznachrichten.de

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

March 17, 2025 | prnewswire.com

When the Price of (INBX) Talks, People Listen

February 12, 2025 | news.stocktradersdaily.com

Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Up 10.07%

January 31, 2025 | aaii.com

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead

January 22, 2025 | msn.com

Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities

January 22, 2025 | markets.businessinsider.com

Inhibrx reports promising ozekibart trial results

January 22, 2025 | msn.com

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

January 21, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ADAP, INBX, and IBRX Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.25 0.00 (-1.17%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.26 +0.01 (+2.37%)

As of 06/20/2025 07:51 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADMA Biologics NASDAQ:ADMA

$17.74 -0.39 (-2.15%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.76 +0.02 (+0.08%)

As of 06/20/2025 07:53 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ImmunityBio NASDAQ:IBRX

$2.87 +0.03 (+1.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.01 (+0.52%)

As of 06/20/2025 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Inhibrx Biosciences NASDAQ:INBX

$14.93 -0.28 (-1.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.97 +0.04 (+0.27%)

As of 06/20/2025 04:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time